ESTRO 36 Abstract Book

S763 ESTRO 36 _______________________________________________________________________________________________

(10.2%) patients developed acute toxicity >2, while 5 patients (6.4%) developed late toxicity >2. Conclusion SBRT is a safe and effective management option for the control of oligometastatic disease . This therapeutic approach can have an important role in delaying disease progression. Toxicity seems to be moderate in most cases EP-1429 maintaining efficacy of low-dose radiotherapy on pain and function in degenerative skeletal diseases B. Alvarez 1 , A. Montero 1 , E. Sanchez 1 , R. Ciervide 1 , F. Aramburu 2 , M. Hernández 1 , M. López 1 , S. Rodríguez 2 , M. Valero 2 , J.J. Valero 1 , M. García-Aranda 1 , E. Calvo 2 , O. Hernando 1 , X. Chen 1 , R. Alonso 3 , P. García de la Peña 2 , C. Rubio 1 1 Hospital universitario hm madrid sanchinarro, Radiation Oncology, Madrid, Spain 2 Hospital universitario hm Madrid sanchinarro, rheumatology, Madrid, Spain 3 Hospital universitario hm puerta del sur, radiation oncology, madrid, Spain Purpose or Objective to evaluate feasibility and duration of response induced by low dose radiotherapy (RT) in patients with painful degenerative diseases comprising enthesiopathies or osteoarthritis refractory to any conventional treatment. Material and Methods From April 2015 to October 2016, 53 patients with painful skeletal disorders of different locations were treated; 16 (30%) patients were monitored for more than six months. The pain was evaluated before radiotherapy and 6 weeks after treatment according to the visual analogue pain scale (VAS) and the requirements of daily oral analgesic intake. All patients underwent CT simulation and were treated in a conventional linac. PTV included the affected joint and periarticular soft tissues. Prescribed dose to the PTV was 6 Gy at 1Gy/fraction each two days. If needed, a second course similar to the previous was delivered after 6-8 All 16 patients were women and the average age was 68 years old. Five treatments were located on hands, 4 on knees, and the 6 remaining at diverse joints. A second course of 6 Gy was required by 50% of patients. Pre-RT median pain score according to VAS was 7.5 (range 4-9); median post-RT pain according to VAS was 1 (range 0-4). There was a reduction of more than 4 points in all patients. Eighty-one per cent of patients reported subjective clinical improvement of their joint pain; 38% of patients reduced their analgesic intake, 6% maintained the same and 31% discontinued oral analgesic. Conclusion Our results support the efficacy and safety of low-dose anti-inflammatory radiotherapy as an alternative treatment for painful osteoarticular degenerative diseases. Pain response and functional improvement maintained for long time in a substantial proportion of patients on follow-up. weeks. Results EP-1430 Venous thromboembolism in radiation oncology: retrospective trial M. Cherkashin 1 , N. Berezina 1 , N. Vorobyov 1 , E. Pinelis 2 1 Dr Berezin Medical Center, Oncology, Saint-Petersburg, Russian Federation 2 Albert Einstein College of Medicine, Respiratory Care, New York, USA Purpose or Objective Venous thromboembolism (VTE) prevention in oncology patients during external beam radiation therapy (RT) in

outpatient setting is the challenging question. There is no clear statement from international societies (ASCO, ESMO, ACCP) and os far it is unclear if RT is an independent risk factor for VTE. Last years a couple of published trials have reported some VTE cases in this group of patients, but lack of evidence is the common problem. The objective of this study is the clear assessment of VTE incidence in these patients Material and Methods In retrospective analysis 3280 patients' medical records were included (1612 with RT and 1668 with chemotherapy). Inclusion criteria were: RT in outpatient setting, chemotherapy in outpatient setting and exclusion criteria: combined radiochemotherapy, hospitalzation, central venous catheter, palliative treatment. 360 patients were selected for the final analysis and were stratified in 3 groups: group I (n=120) 3D-conformal RT for brain tumors or brain metastasis; group II (n=120) RT for body tumors (abdominal, retroabdominal, pelvic, chest, breast); group III (n=120) was control –brain and body tumors on chemotherapy. Mean fraction numbers were 25 (11 - 32), mean total dose – 52 Gy (22 - 66). VTE assessment based on clinical data, venous ultrasound examination (US) and chest CT. Statistical analysis was performed by OpenEpi, Version 3 software pack. Results Deep vein thrombosis (DVT) was detected in 7 cases (5.8%) in group I, 2 cases in group II and 1 case in control group. VTE patients has a different tumors (right parietal area astrocytoma, brain trunk tumor, skull basis cancer, rectal cancer, breast cancer). 3 patients were available for long- term outcomes assessment (12 months after radiation therapy). During 1-year period we haven’t detected thrombosis recurrence. Post thrombotic disease had developed but without severe venous insufficiency. One patient on 11th follow-up month was exposed with repeated course of RT without any complications. The difference between VTE incidence for group I and group III characterized by statistical significance (p=0.018). Risk difference for these groups was 5% (p<0.05). Conclusion Based on study results we suggest that external beam radiation therapy is potentially an independent risk factor for venous thromboembolism development even in outpatient settings. High degree of clinical suspicion and aggressive diagnostic work-up in case of suspicion is necessary. In our opinion VTE prevention with low molecular weight or unfractionated heparin should be considered in selected patients at least during active radiation therapy E. Burchardt 1 , A. Roszak 2 , B. Urbañski 3 , A. Nowak 3 1 Greater Poland Cancer Centre, Department of Oncological Gynecology and Radiotherapy, Poznan, Poland 2 Greater Poland Cancer Centre, oncological gynecology and radiotherapy, Poznań, Poland 3 Greater Poland Cancer Centre, Department of Oncological Gynecology and Radiotherapy, Poznań, Poland Purpose or Objective A series of phase III trials demonstrated the clinical effect of hyperthermia. In January 2016 a new device for deep regional hyperthermia was installed in our cancer centre. The aim of this study was to assess tolerance and acute toxicity of loco-regional hyperthermia given during EP-1431 Acute toxicity in deep loco-regional hyperthermia

oncological treatment. Material and Methods

101 patients (pts) were evaluated during treatment in the period of time from January till September 2016. 45 pts